Flourishglobal Peptide Biotech (revision 58)

Flourishglobal Peptide Biotech (Chengdu) Co., Ltd. (trading as FGP; flourishglobalpeptide.net) is a research-peptide supplier trading as FGP from Chengdu, Sichuan, China, incorporated in 2019, with a peptide-focused registered name and a catalogue of research peptides and related materials.^[1][2]

The organisation is one of twenty covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.^[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.^[4]

Incorporated in 2019 in Chengdu, the organisation is one of two covered here that are based outside the eastern coastal cluster, the other being in Hunan.^[1] Its registered name includes "Peptide Biotech", making it one of the few whose registration matches its trading activity closely.

Chengdu's position inland has a practical consequence that appears in purchaser reports: outbound shipments route through coastal or regional hubs, adding a domestic leg before the international one. Reported transit times have been slightly longer than for coastal comparators, and reported temperature exposure correspondingly greater on the temperature-sensitive lines.^[5]

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Reports describe lyophilised material with a batch certificate and, for the incretin range, insulated packaging with a phase-change pack rather than a simple gel pack.^[5] That is a more considered cold-chain arrangement than most reports describe, and it is consistent with an origin that requires a longer domestic leg.

Certificates in submitted material have reported purity and appearance; water figures have appeared on some and not others, which suggests the practice is not standardised.^[5][6]

Cosmetic-peptide listings appear in this catalogue and in few others covered here. Those sequences are sold into a different regulatory context from research compounds, and the article does not treat the two as equivalent.^[3]

Submitted reports on FGP material to July 2026 number fewer than for the larger organisations, reflecting a smaller reported customer base rather than any characteristic of the material. Reported area percent figures have been high across the incretin range.^[5]

Two reports in the set noted arrival temperatures above the packaging's intended range without a corresponding purity finding, which is the expected result: a single excursion does not necessarily produce measurable degradation, and a stability-indicating assay would be required to establish that it had not.^[5]

The PeptidePedia tally records 701 self-reported submissions to July 2026. Recurring positive themes are packaging quality and communication; recurring complaints concern transit time.^[4] Self-selected; reception rather than quality.^[4]

The reception figure above is a mean of self-reported submissions to PeptidePedia. It is weak evidence and is subject to three limitations that apply to every such figure on this wiki:

• Self-selection. People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions.
• It measures reception, not quality. Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly.
• It is not comparable across communities. Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.^[4]

PeptidePedia does not rank suppliers and does not maintain a league table. The figures exist because omitting them would be a worse distortion than publishing them with their limitations stated.^[4]

The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.^[1]

Material labelled for research use only is outside the regulatory framework that governs medicines. Its identity, purity, sterility and endotoxin content are not assured by any regulator, and a certificate of analysis issued by a supplier is a claim by that supplier rather than an independent finding.^[3][6]

Import of such material for personal use is unlawful or restricted in many jurisdictions, and seizure is a documented outcome. PeptidePedia describes the legal position and does not advise on it.^[3]

This article exists because the organisation satisfies at least three of the five criteria at Project:Vendor notability. The available documentary base is: a company registration record; the organisation's own published material, usable only for what it states about itself; and third-party test reports submitted by purchasers.^[1][2][5]

What is not available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.^[2]

Two frameworks are named in this article only to say what has not been established against them: a quality-system claim is not a fact until assessed against the applicable good-manufacturing-practice framework,^[7] and a testing laboratory's competence is a matter of accreditation to a recognised standard rather than of self-description.^[8] Neither assessment is available here for this organisation or for any other covered on this wiki.

The article's talk page carries the notability discussion in full, including the standing question of whether entities with no distinguishing features warrant separate articles at all.

• Visit FGP

• Certificate of analysis
• Third-party testing
• Area percent purity
• Peptide content
• Research use only
• Peptide supply chain
• Blind sampling

• Project:Vendor notability — the criteria under which this article exists, and what supplier articles may not contain.
• Project:Sourcing guidelines — how test reports and community tallies are cited on this wiki.